Showing results (291-300 of 648) with videos related to
Sort By:
Pageof 65
Hemasphere|February 26, 2026
Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groupsAlina M Hartmann, Lorenz Bastian, Malwine J Barz, et al.Hemasphere|March 9, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignanciesElise R A Pennings, Frederick W Thielen, Florence Broussais, et al.Hemasphere|February 26, 2026
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosisBarbara Mora, Matteo Franchi, Ludovica Margotto, et al.Hemasphere|April 10, 2026
Erdheim-Chester disease associated with myeloid neoplasm: Clinical features, molecular landscape, and treatment outcomesAmbroise Le Pogam, Matthias Papo, Pierre Hirsch, et al.Hemasphere|April 20, 2026
Biological and clinical characteristics of ETV6::RUNX1-like ALLMarketa Zaliova, Dagmar Schinnerl, Judith M Boer, et al.Hemasphere|April 27, 2026
A microRNA expression signature in infant t(4;11) KMT2A::AFF1+ BCP-ALL uncovers novel therapeutic targetsCamille Malouf, Alasdair Duguid, Kirsten S Vrenken, et al.Hemasphere|April 24, 2026
Functional, biochemical, and clinical characterization of natural mutations affecting arginine residues in the heparin-binding site of antithrombinRosa Cifuentes-Riquelme, María Eugenia de la Morena-Barrio, Antonia Miñano, et al.Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.Hemasphere|June 8, 2026
A RiboCancer cell line panel reveals that CLL-associated Rps15 mutations translationally rewire transcription through codon-specific tRNA accommodation defectsAnaïs Astier, Marino Caruso, Stijn Vereecke, et al.Pageof 65